A similar trend was obtained by measuring GCase activity in plasma from a small pilot cohort (see the section “Materials and methods”) constituted by LRRK2 G2019S PD patients, GBA1 PD patients, iPD patients and controls (Fig. 2d) (one-way ANOVA with Tukey’s post test). This evidence concerns the gene LRRK2 and Parkinson disease.